We are live on ! Find out more
HBIO icon

Harvard Bioscience
HBIO

60 hedge funds and large institutions have $54.2M invested in Harvard Bioscience in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.06% less ownership

Funds ownership: 6.2% → 6.14% (-0.06%)

3% less capital invested

Capital invested by funds: $55.8M → $54.2M (-$1.55M)

3% less funds holding

Funds holding: 62 → 60 (-2)

20% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 20

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
60
Holders Change
-2
Holders Change %
-3.23%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
16
Reduced
20
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SBH
Segall Bryant & Hamill
Illinois
+$1.08M
2
FLAM
First Light Asset Management
Minnesota
+$910K
3
Ameriprise
Ameriprise
Minnesota
+$729K
4
BCM
Bridgeway Capital Management
Texas
+$474K
5
EIM
Essex Investment Management
Massachusetts
+$297K

Top Sellers

Rank Fund Capital Flow
1
GIM
Granahan Investment Management
Massachusetts
-$1.78M
2
KCM
Kennedy Capital Management
Missouri
-$1.28M
3
JAM
Jupiter Asset Management
United Kingdom
-$1.1M
4
USAA
United Services Automobile Association
Texas
-$171K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$160K
Name Holding Trade Value Shares
Change 		Change in
Stake
JC
51
JBF Capital
Colorado
$16K – – –
AIM
52
Acrospire Investment Management
Illinois
$9K -$75K -3,032 -90%
UBS Group
53
UBS Group
Switzerland
$9K -$1.34K -54 -13%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K +$445 +18 +10%
Wells Fargo
55
Wells Fargo
California
$4K -$4.95K -200 -56%
Northwestern Mutual Wealth Management
56
Northwestern Mutual Wealth Management
Wisconsin
$3K +$2.45K +99 New
Creative Planning
57
Creative Planning
Kansas
$2K +$2K +81 New
SEI Investments
58
SEI Investments
Pennsylvania
$1K -$223 -9 -24%
LTFS
59
Ladenburg Thalmann Financial Services
Florida
$1K – – –
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$5 – – –
KCM
61
Kennedy Capital Management
Missouri
– -$1.28M -49,091 Closed
Jacobs Levy Equity Management
62
Jacobs Levy Equity Management
New Jersey
– -$160K -6,147 Closed
Millennium Management
63
Millennium Management
New York
– -$43K -1,644 Closed
BRWA
64
B. Riley Wealth Advisors
Florida
– -$32K -1,180 Closed
Walleye Trading
65
Walleye Trading
New York
– -$18 -680 Closed
1 2
3

HBIO Hedge Fund Activity: Q2 2017 in Review

60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2017, worth a combined $54.2M — down 2.8% from $55.8M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of HBIO and 4 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 16 added.

The largest buyer was Segall Bryant & Hamill, adding an estimated $1.08M. The largest seller was Granahan Investment Management, cutting an estimated $1.78M.

  • 60 institutional investors held Harvard Bioscience (HBIO) as of Q2 2017, down from 62 in Q1 2017.
  • Funds reported $54.2M of Harvard Bioscience stock for Q2 2017, down 2.8% quarter-over-quarter.
  • 4 funds opened new Harvard Bioscience positions in Q2 2017 and 6 closed out, a net change of -2 holders.
  • The largest Harvard Bioscience buyer in Q2 2017 was Segall Bryant & Hamill, an estimated $1.08M added.
  • The largest Harvard Bioscience seller in Q2 2017 was Granahan Investment Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q2 2017.